Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Account Payables (2020 - 2025)

Apellis Pharmaceuticals has reported Change in Account Payables over the past 6 years, most recently at $18.2 million for Q4 2025.

  • Quarterly results put Change in Account Payables at $18.2 million for Q4 2025, up 1122.78% from a year ago — trailing twelve months through Dec 2025 was $18.2 million (up 1573.37% YoY), and the annual figure for FY2025 was $18.2 million, up 1573.37%.
  • Change in Account Payables for Q4 2025 was $18.2 million at Apellis Pharmaceuticals, up from -$15.6 million in the prior quarter.
  • Over the last five years, Change in Account Payables for APLS hit a ceiling of $23.1 million in Q4 2022 and a floor of -$15.6 million in Q3 2025.
  • Median Change in Account Payables over the past 5 years was -$481000.0 (2021), compared with a mean of $2.4 million.
  • Biggest five-year swings in Change in Account Payables: plummeted 8567.47% in 2022 and later soared 1122.78% in 2025.
  • Apellis Pharmaceuticals' Change in Account Payables stood at $13.7 million in 2021, then soared by 68.8% to $23.1 million in 2022, then dropped by 15.16% to $19.6 million in 2023, then crashed by 92.42% to $1.5 million in 2024, then soared by 1122.78% to $18.2 million in 2025.
  • The last three reported values for Change in Account Payables were $18.2 million (Q4 2025), -$15.6 million (Q3 2025), and -$1.0 million (Q2 2025) per Business Quant data.